Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Pfizer (NYSE:PFE) and maintains a $45 price target.
April 15, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald reaffirms an Overweight rating on Pfizer, with a $45 price target.
The reiteration of an Overweight rating and maintenance of a $45 price target by a reputable analyst could signal confidence in Pfizer's future performance, potentially influencing investor sentiment positively in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100